Company Focus
Merck & Co
Latest Merck & Co News
Pharmaceutical
Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), a progressive lung disease that can lead to respiratory failure and severely limit quality of life, according to data and analytics group GlobalData. 13 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Merck & Co
Pharmaceutical
Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), a progressive lung disease that can lead to respiratory failure and severely limit quality of life, according to data and analytics group GlobalData. 13 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Pharmaceutical
Evotec reported second-quarter 2025 revenues of $188 million, down 6% year-on-year, as strength in its biologics division partly offset weaker demand in discovery and preclinical services. Net loss narrowed to $48 million from $103 million, with earnings per share at minus $0.24. 13 August 2025
Pharmaceutical
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s Brinsupri (brensocatib) tablets to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory lung condition, in patients ages 12 years and older. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 clinical trial (also known as KEYNOTE-905). 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Biotechnology
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 12 August 2025
Biotechnology
Shanghai Fosun Pharma has signed a license agreement with Expedition Therapeutics, granting the latter rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. 12 August 2025
Latest In Brief for Merck & Co
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Related Ones To Watch News
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
28 July 2025
18 July 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze